Avicanna Introduces a New Medical Cannabis Education Online Portal, “Avicenna Academy” for Health Care Professionals
18 October 2022 - 10:30PM
Avicanna Inc. (“
Avicanna” or the
“
Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN),
a commercial stage, international biopharmaceutical company focused
on the commercialization of evidence-based, cannabinoid-based
products, is pleased to announce that it has launched its medical
cannabis education portal, ”Avicenna Academy”, a no-cost resource
and medical education portal for Health Care Professionals
(“HCPs”). The medical education portal is designed
to support HCPs through education and practical information with
respect to the potential use of medical cannabis, with a view
towards expanding access as well as measuring patient outcomes.
Avicenna Academy
https://avicenna-academy.teachable.com
The Avicenna Academy is designed to address the
potential gaps in understanding cannabinoid-based products while
making available resources and information which may be tools for
the medical community. Towards that goal, Avicanna’s medical team
has combined its research and development expertise with
cannabinoid formulations utilizing advanced drug delivery systems.
Practical experience in delivering RHO PhytoTM medical cannabis
products through established medical portals, pharmacies, major
hospitals both in Canada and international markets has allowed
Avicanna to develop various educational resources such as
downloadable guides, online modules, and access to discussions with
key opinion leaders across a range of medical specialities.
The portal currently includes a range of
resources including HCP guidelines and supporting information
regarding medical authorization documentation for patients in
Canada.
The preliminary set of modules cover a
range of topics including:
- The history of
medical cannabis use
- The
endocannabinoid system
- Potential
therapeutic targets
- The current
state of evidence
- Dosing and
titration overview
- Case studies and
practical use
The Avicenna Academy looks towards expanding
offerings in the portal that are reflective of on-going research in
the field. Access to the Avicenna Academy will be offered at no
cost for HCPs to support necessary education and training. The
company is actively collaborating with the medical community to
improve this current initiative and is also working toward building
indication-specific modules in collaboration with Canadian and
international key opinion leaders and experts in their respective
fields.
“We are excited about the launch of this
Platform as a resource that facilitates information and education
to potentially improve patient outcomes and foster further
collaboration with the medical community,” stated Aras Azadian,
CEO, Avicanna Inc.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
Medical Cannabis & Wellness
Products: Marketed under the RHO Phyto™ brand these
medical and wellness products are a line of pharmaceutical-grade
cannabinoid products containing varying ratios of cannabidiol
(“CBD”) and tetrahydrocannabinol (“THC”). The product portfolio
contains a full formulary of products including oral, sublingual,
topical, and transdermal deliveries that have controlled dosing,
enhanced absorption and stability studies supported by pre-clinical
data. The formulary is marketed with consumer, patient and
medical-community education and training.
Pharmaceutical
Pipeline: Leveraging Avicanna’s scientific platform,
vertical integration, and real-world evidence, Avicanna has created
a pipeline of patent-pending drug candidates that are
indication-specific and in various stages of clinical development
and commercialization. These cannabinoid-based drug candidates look
to address unmet medical needs in the areas of dermatology, chronic
pain, and various neurological disorders. Avicanna’s first
pharmaceutical preparation (Trunerox™) is in the drug registration
stage in South America.
Click to watch Avicanna’s Corporate Video
2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit
www.avicanna.com, contact Ivana Maric by email at info@avicanna.com
or follow us on social media
on LinkedIn, Twitter, Facebook or Instagram.
If you are a Healthcare Professional and would
like to learn more about using medical cannabis in your practice,
please visit Avicenna Academy.
The Company posts updates through videos from
the official Company YouTube channel.
Cautionary Note Regarding
Forward-Looking Information and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified by the use of words such as, “may”, “would”, “could”,
“will”, “likely”, “expect”, “anticipate”, “believe, “intend”,
“plan”, “forecast”, “project”, “estimate”, “outlook” and other
similar expressions. Forward-looking information contained in this
news release includes, without limitation, statements with respect
to the Company’s future business operations, potential
collaborations, the opinions or beliefs of management and future
business goals. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include, but are not
limited to, current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2022, filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
A photo accompanying this announcement is
available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/7823816b-08dc-4012-8a50-4303fbd85291
Avicanna (TSX:AVCN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
From Mar 2023 to Mar 2024